Humans will be able to replace their bodies within 50 years claims transhumanist writer – Express.co.uk

Transhumanists believe humans can and should use technology to artificially augment their capabilities.Natasha Vita-More is Executive Director of Humanity+, formerly the World Transhumanist Association, and is one of the co-authors of the 1998 Transhumanist Declaration.

Speaking toExpress.co.ukshe said: We certainly do need to upgrade our biology and Ive been speaking about this for 30-something years.

The fact that our biology is vulnerable. We exist on a daily basis with an incredible vulnerable vehicle, our bodies, that anything could go wrong at any time.

As far as genetic engineering goes weve seen great work done with certain diseases like Tay-Sachs and sickle-cell anemia, certain cancers, certain diseases that handicap us.

Other gene therapies are in the works and there still needs to be far more work in this area and I think most of us will be undergoing gene therapy as soon as it comes online as needed.

Say 50 years from now I think well be looking at alternative bodies and we can see that really growing in the field of prosthetics.

Transhumanists think human lifespans can be radically extended, with many believing ageing can be reversed and death from disease abolished.

Ms Vita-More argued future humans will look to backup the content of their brains as an insurance policy against death or injury.

She asserted: It is essential our memories be stored some place.

Currently our memories are stored in our brain but thats vulnerable. We have hackers all the time in our brains and those are called viruses and disease.

Disease is constantly hacking our neurons so in order to protect that we need to have copies of it, we need to back it up and you see certain industry leaders like Google looking at how to back up the brain.

I see uploading as a necessary technology for not only backing up the brain but as a means for us to go into different environments.

Were currently in this physical/material world, this biosphere, there are other worlds yet to be explored just as were looking at space exploration.

READ MORE:Oxford academic claims future humans could live for thousands of years

Another area is virtual reality, augmented reality, all these other systems even in games to go into games and participate as yourself taking on an avatar or maybe something else.

Asked about those who might object, on religious or moral grounds, to radical life extension Ms Vita-More expressed confidence their arguments would be overcome.

She commented: I think its largely religious but I think it is also innate.

I think the narrative is engrained in culturalization, it seems to be endemic across cultures.

Given that plus the largest percentage of people on our planet are religious that puts a damper on it too. However it doesnt prevent it.

It could be interesting if we see religious doctrines changing a little bit to include life extension and changing as weve seen with divorce.

If you believe an afterlife it doesnt have to happen at exactly a certain time. Maybe instead of 90 as a lifespan maybe 300 if you want to go that route.

So well see a realisation that religions have to keep up with the state of society and their members within that.

Ms Vita-More is also an advisor to the Singularity University and co-editor and contributing author to The Transhumanist Reader: Classical and Contemporary Essays on the Science, Technology, and Philosophy of the Human Future.

Asked what most excites her about the future she replied: I would like to totally reengineer my body, its not available yet but Id like to have a whole new body thats smoothly integrated not only with narrow artificial intelligence (AI) but with artificial general intelligence and Id like to have a metabrain where Id have AI working with me like a best friend or cohort.

Excerpt from:

Humans will be able to replace their bodies within 50 years claims transhumanist writer - Express.co.uk

How Britain’s oldest universities are trying to protect humanity from risky A.I. – CNBC

University of Oxford

Oli Scarff/Getty Images

Oxford and Cambridge, the oldest universities in Britain and two of the oldest in the world, are keeping a watchful eye on the buzzy field of artificial intelligence (AI), which has been hailed as a technology that will bring about a new industrial revolution and change the world as we know it.

Over the last few years, each of the centuries-old institutions have pumped millions of pounds into researching the possible risks associated with machines of the future.

Clever algorithms can already outperform humans at certain tasks. For example, they can beat the best human players in the world at incredibly complex games like chess and Go, and they're able to spot cancerous tumors in a mammogram far quicker than a human clinician can. Machines can also tell the difference between a cat and a dog, or determine a random person's identity just by looking at a photo of their face. They can also translate languages, drive cars, and keep your home at the right temperature. But generally speaking, they're still nowhere near as smart as the average 7-year-old.

The main issue is that AI can't multitask. For example, a game-playing AI can't yet paint a picture. In other words, AI today is very "narrow" in its intelligence. However, computer scientists at the the likes of Google and Facebook are aiming to make AI more "general" in the years ahead, and that's got some big thinkers deeply concerned.

Nick Bostrom, a 47-year-old Swedish born philosopher and polymath, founded the Future of Humanity Institute (FHI) at the University of Oxford in 2005 to assess how dangerous AI and other potential threats might be to the human species.

In the main foyer of the institute, complex equations beyond most people's comprehension are scribbled on whiteboards next to words like "AI safety" and "AI governance." Pensive students from other departments pop in and out as they go about daily routines.

It's rare to get an interview with Bostrom, a transhumanist who believes that we can and should augment our bodies with technology to help eliminate ageing as a cause of death.

"I'm quite protective about research and thinking time so I'm kind of semi-allergic to scheduling too many meetings," he says.

Tall, skinny and clean shaven, Bostrom has riled some AI researchers with his openness to entertain the idea that one day in the not so distant future, machines will be the top dog on Earth. He doesn't go as far as to say when that day will be, but he thinks that it's potentially close enough for us to be worrying about it.

Swedish philosopher Nick Bostrom is a polymath and the author of "Superintelligence."

The Future of Humanity Institute

If and when machines possess human-level artificial general intelligence, Bostrom thinks they could quickly go on to make themselves even smarter and become superintelligent. At this point, it's anyone's guess what happens next.

The optimist says the superintelligent machines will free up humans from work and allow them to live in some sort of utopia where there's an abundance of everything they could ever desire. The pessimist says they'll decide humans are no longer necessary and wipe them all out.Billionare Elon Musk, who has a complex relationship with AI researchers, recommended Bostrom's book "Superintelligence" on Twitter.

Bostrom's institute has been backed with roughly $20 million since its inception. Around $14 million of that coming from the Open Philanthropy Project, a San Francisco-headquartered research and grant-making foundation. The rest of the money has come from the likes of Musk and the European Research Council.

Located in an unassuming building down a winding road off Oxford's main shopping street, the institute is full of mathematicians, computer scientists, physicians, neuroscientists, philosophers, engineers and political scientists.

Eccentric thinkers from all over the world come here to have conversations over cups of tea about what might lie ahead. "A lot of people have some kind of polymath and they are often interested in more than one field," says Bostrom.

The FHI team has scaled from four people to about 60 people over the years. "In a year, or a year and a half, we will be approaching 100 (people)," says Bostrom. The culture at the institute is a blend of academia, start-up and NGO, according to Bostrom, who says it results in an "interesting creative space of possibilities" where there is "a sense of mission and urgency."

If AI somehow became much more powerful, there are three main ways in which it could end up causing harm, according to Bostrom. They are:

"Each of these categories is a plausible place where things could go wrong," says Bostrom.

With regards to machines turning against humans, Bostrom says that if AI becomes really powerful then "there's a potential risk from the AI itself that it does something different than anybody intended that could then be detrimental."

In terms of humans doing bad things to other humans with AI, there's already a precedent there as humans have used other technological discoveries for the purpose of war or oppression. Just look at the atomic bombings of Hiroshima and Nagasaki, for example. Figuring out how to reduce the risk of this happening with AI is worthwhile, Bostrom says, adding that it's easier said than done.

I think there is now less need to emphasize primarily the downsides of AI.

Asked if he is more or less worried about the arrival of superintelligent machines than he was when his book was published in 2014, Bostrom says the timelines have contracted.

"I think progress has been faster than expected over the last six years with the whole deep learning revolution and everything," he says.

When Bostrom wrote the book, there weren't many people in the world seriously researching the potential dangers of AI. "Now there is this thriving small, but thriving field of AI safety work with a number of groups," he says.

While there's potential for things to go wrong, Bostrom says it's important to remember that there are exciting upsides to AI and he doesn't want to be viewed as the person predicting the end of the world.

"I think there is now less need to emphasize primarily the downsides of AI," he says, stressing that his views on AI are complex and multifaceted.

Bostrom says the aim of FHI is "to apply careful thinking to big picture questions for humanity." The institute is not just looking at the next year or the next 10 years, it's looking at everything in perpetuity.

"AI has been an interest since the beginning and for me, I mean, all the way back to the 90s," says Bostrom. "It is a big focus, you could say obsession almost."

The rise of technology is one of several plausible ways that could cause the "human condition" to change in Bostrom's view. AI is one of those technologies but there are groups at the FHI looking at biosecurity (viruses etc), molecular nanotechnology, surveillance tech, genetics, and biotech (human enhancement).

A scene from 'Ex Machina.'

Source: Universal Pictures | YouTube

When it comes to AI, the FHI has two groups; one does technical work on the AI alignment problem and the other looks at governance issuesthat will arise as machine intelligence becomes increasingly powerful.

The AI alignment group is developing algorithms and trying to figure out how to ensure complex intelligent systems behave as we intend them to behave. That involves aligning them with "human preferences," says Bostrom.

Roughly 66 miles away at the University of Cambridge, academics are also looking at threats to human existence, albeit through a slightly different lens.

Researchers at the Center for the Study of Existential Risk (CSER) are assessing biological weapons, pandemics, and, of course, AI.

We are dedicated to the study and mitigation of risks that could lead to human extinction or civilization collapse.

Centre for the Study of Existential Risk (CSER)

"One of the most active areas of activities has been on AI," said CSER co-founder Lord Martin Rees from his sizable quarters at Trinity College in an earlier interview.

Rees, a renowned cosmologist and astrophysicist who was the president of the prestigious Royal Society from 2005 to 2010, is retired so his CSER role is voluntary, but he remains highly involved.

It's important that any algorithm deciding the fate of human beings can be explained to human beings, according to Rees. "If you are put in prison or deprived of your credit by some algorithm then you are entitled to have an explanation so you can understand. Of course, that's the problem at the moment because the remarkable thing about these algorithms like AlphaGo (Google DeepMind's Go-playing algorithm) is that the creators of the program don't understand how it actually operates. This is a genuine dilemma and they're aware of this."

The idea for CSER was conceived in the summer of 2011 during a conversation in the back of a Copenhagen cab between Cambridge academic Huw Price and Skype co-founder Jaan Tallinn, whose donations account for 7-8% of the center's overall funding and equate to hundreds of thousands of pounds.

"I shared a taxi with a man who thought his chance of dying in an artificial intelligence-related accident was as high as that of heart disease or cancer," Price wrote of his taxi ride with Tallinn. "I'd never met anyone who regarded it as such a pressing cause for concern let alone anyone with their feet so firmly on the ground in the software business."

University of Cambridge

Geography Photos/UIG via Getty Images

CSER is studying how AI could be used in warfare, as well as analyzing some of the longer term concerns that people like Bostrom have written about. It is also looking at how AI can turbocharge climate science and agricultural food supply chains.

"We try to look at both the positives and negatives of the technology because our real aim is making the world more secure," says Sen higeartaigh, executive director at CSER and a former colleague of Bostrom's. higeartaigh, who holds a PhD in genomics from Trinity College Dublin, says CSER currently has three joint projects on the go with FHI.

External advisors include Bostrom and Musk, as well as other AI experts like Stuart Russell and DeepMind's Murray Shanahan. The late Stephen Hawking was also an advisor when he was alive.

The Leverhulme Center for the Future of Intelligence (CFI) was opened at Cambridge in 2016 and today it sits in the same building as CSER, a stone's throw from the punting boats on the River Cam. The building isn't the only thing the centers share staff overlap too and there's a lot of research that spans both departments.

Backed with over 10 million from the grant-making Leverhulme Foundation, the center is designed to support "innovative blue skies thinking," according to higeartaigh, its co-developer.

Was there really a need for another one of these research centers? higeartaigh thinks so. "It was becoming clear that there would be, as well as the technical opportunities and challenges, legal topics to explore, economic topics, social science topics," he says.

"How do we make sure that artificial intelligence benefits everyone in a global society? You look at issues like who's involved in the development process? Who is consulted? How does the governance work? How do we make sure that marginalized communities have a voice?"

The aim of CFI is to get computer scientists and machine-learning experts working hand in hand with people from policy, social science, risk and governance, ethics, culture, critical theory and so on. As a result, the center should be able to take a broad view of the range of opportunities and challenges that AI poses to societies.

"By bringing together people who think about these things from different angles, we're able to figure out what might be properly plausible scenarios that are worth trying to mitigate against," said higeartaigh.

Original post:

How Britain's oldest universities are trying to protect humanity from risky A.I. - CNBC

Heres Everything Coming to HBO Max in June – TheWrap

HBO Max launches May 27 with a whole lot of content ready to stream immediately. But throughout the nascent streamers first month, even more titles will be added, from HBO Max originals like Adventure Time: Distant Lands BMO, to old favorites like Amelie, Black Beauty and The Bucket List.

Other brand-new HBO Max originals include the third season of comedy Search Party, and the second seasons of Doom Patrol, and Esme & Roy, all coming June 25, and on June 18, the second season of Summer Camp Island and the series premiere kids competition series Karma.

For a list of everything that will be available on launch day, look here.

Below is the full list of everything new coming to HBO Max in June.

Also Read: Chelsea Handler Sets First Standup Comedy Special in 6 Years at HBO Max

June 14th & Forever: Muck City, Season OneAdventures In Babysitting, 1987 (HBO)Amelie, 2001 (HBO)An American Werewolf in London, 1981 (HBO)The American, 2010 (HBO)Another Cinderella Story, 2008Beautiful Girls, 1996 (HBO)Black Beauty, 1994Bridget Joness Baby, 2016The Bucket List, 2007Cabaret, 1972The Champ, 1979Chicago, 2002A Cinderella Story, 2004A Cinderella Story: Once Upon a Song, 2011Clash Of The Titans, 2010Cradle 2 the Grave, 2003Crash, 2005 (Directors Cut) (HBO)Doubt, 2008 (HBO)Dreaming Of Joseph Lees, 1999 (HBO)Drop Dead Gorgeous, 1999Dune, 1984 (HBO)Elf, 2003Enter The Dragon, 1973Far and Away, 1992 (HBO)Final Destination, 2000Final Destination 2, 2003Final Destination 3, 2006The Final Destination, 2009Firewall, 2006Flipped, 2010Forces of Nature, 1999 (HBO)The Fountain, 2006 (HBO)Frantic, 1988From Dusk Til Dawn, 1996Full Metal Jacket, 1987Gente De Zona: En Letra De Otro, 2018 (HBO)The Good Son, 1993 (HBO)The Goonies, 1985Hanna, 2011 (HBO)Havana, 1990 (HBO)He Got Game, 1998 (HBO)Heaven Can Wait, 1978Heidi, 2006Hello Again, 1987 (HBO)The Hobbit: An Unexpected Journey, 2012The Hobbit: The Desolation of Smaug, 2013The Hunger, 1983In Her Shoes, 2005 (HBO)In Like Flint, 1967 (HBO)The Iron Giant, 1999It Takes Two, 1995Juice, 1992The Last Mimzy, 2007License To Wed, 2007Life, 1999 (HBO)Lifeforce, 1985 (HBO)Lights Out, 2016 (HBO)Like Water For Chocolate, 1993 (HBO)Looney Tunes: Back in Action, 2003The Losers, 2010Love Jones, 1997Lucy, 2020 (HBO)Magic Mike, 2012McCabe and Mrs. Miller, 1971Misery, 1990Miss Pettigrew Lives for a Day, 2008 (HBO)A Monster Calls, 2016 (HBO)Mr. Wonderful, 1993 (HBO)Must Love Dogs, 2005My Dog Skip, 2000Mystic River, 2003The Neverending Story II: The Next Chapter, 1991The Neverending Story, 1984New York Minute, 2004Nights In Rodanthe, 2008No Reservations, 2007Ordinary People, 1980Our Man Flint, 1966 (HBO)The Parallax View, 1974Patch Adams, 1998 (HBO)A Perfect World, 1993Pedro Capo: En Letra Otro, 2017 (HBO)Personal Best, 1982Presumed Innocent, 1990Ray, 2004 (HBO)Richie Rich (Movie), 1994Rosewood, 1997Rugrats Go Wild, 2003Running on Empty, 1988Secondhand Lions, 2003Shes The Man, 2006 (HBO)Sherlock Holmes: A Game of Shadows, 2011 (HBO)Space Cowboys, 2000Speed Racer, 2008Splendor in the Grass, 1961The Stepfather, 1987 (HBO)Summer Catch, 2001Teenage Mutant Ninja Turtles, 1990Teenage Mutant Ninja Turtles 2, 1991Teenage Mutant Ninja Turtles 3, 1993Tess, 1980 (HBO)Tim Burtons Corpse Bride, 2005The Time Travelers Wife, 2009Titanic, 1997TMNT, 2007Torch Song Trilogy, 1988Turbo: A Power Rangers Movie, 1997 (HBO)Tweetys High-Flying Adventures, 2000U-571, 2000 (HBO)U.S. Marshals, 1998Unaccompanied Minors, 2006Uncle Buck, 1989 (HBO)Veronica Mars, 2014Walking and Talking, 1996 (HBO)We Are Marshall, 2006Weird Science, 1985 (HBO)When Harry Met Sally, 1989Wild Wild West, 1999Wonder, 2019 (HBO)X-Men: First Class, 2011 (HBO)Youve Got Mail, 1998

Also Read: Here's How You Can Get HBO Max if You Already Pay for HBO

June 2Inside Carbonaro, Season One (TruTV)

June 4HBO First Look: The King of Staten Island (HBO)Were Here, Season Finale (HBO)

June 5Betty, Season Finale (HBO)

June 6Ad Astra, 2019 (HBO)Yvonne Orji: Momma, I Made It! (HBO)

June 7I May Destroy You, Series Premiere (HBO)

June 10Infinity Train, Season 2 Premiere

June 12El asesino de los caprichos (AKA The Goya Murders), 2020 (HBO)

June 13The Good Liar, 2019 (HBO)

June 14I Know This Much Is True, Limited Series Finale (HBO)Insecure, Season 4 Finale (HBO)

June 16#GeorgeWashington, 2017Age of Big Cats, Season OneAncient Earth, Season OneApocalypse: WWI, Season OneBig World in A Small Garden, 2016The Celts: Blood, Iron & Sacrifice, Season OneCornfield Shipwreck, 2019The Daunting Fortress of Richard the Lionheart, 2019David Attenboroughs Ant Mountain, 2016David Attenbouroughs Light on Earth, 2016DeBugged, 2018Digits, Season OneDragons & Damsels, 2019Ebony: The Last Years of The Atlantic Slave Trade, 2016Expedition: Black Sea Wrecks, Season OneFirst Man, 2017Going Nuts: Tales from Squirrel World, 2019Hack the Moon: Unsung Heroes of Apollo, 2019The History of Food, Season OneHurricane the Anatomy, Season One, 2018Into the Lost Crystal Caves, 2016Jason Silva: Transhumanism, 2016King: A Filmed Record Montgomery to Memphis (Part 1 & Part 2), Season OneKnuckleball!, 2019Leonardo: The Mystery of The Lost Portrait, 2018Looney Tunes (Batch 2) (6/22), Season OneMans First Friend, 2018Penguin Central, 2019Pompeii: Disaster Street, 2020Popeye (Batch 2) (6/22), Season OnePyramids Builders: New Clues, 2019Realm of the Volga, Season OneSacred Spaces, Season OneScandalous: The Untold Story of the National Enquirer, Documentary Premiere (CNN)

Scanning the Pyramids, 2018Science vs. Terrorism, Season OneThe Secret Lives of Big Cats, Season OneSecret Life of Lakes, Season OneSecret Life Underground, Season OneSecrets of the Solar System, Season OneSpace Probes!, Season OneSpeed, Season OneSpies of War , Season OneTales of Nature, Season OneTsunamis: Facing a Global Threat, 2020Versailles Rediscovered: The Sun Kings Vanished Palace, 2019Viking Women, Season OneVitamania, 2018Whale Wisdom, 2019The Woodstock Bus, 2019

Also Read: Here Are the TV Shows and Movies That Will Be Available on HBO Max at Launch

June 18Summer Camp Island, Season 2 PremiereKarma, Series Premiere

June 19Bully. Coward. Victim. The Story of Roy Cohn, Documentary Premiere (HBO)Entre Nos: The Winners (HBO)Bajo el mismo techo (AKA Under the Same Roof), 2020 (HBO)

June 20Ford V. Ferrari, 2020 (HBO)

June 21Perry Mason, Limited Series Premiere (HBO)

June 22Hard, Series Finale (HBO)

June 24South Park, Seasons 1-23Transhood, Documentary Premiere (HBO)

June 25Adventure Time Distant Lands: BMO, Special Premiere

Doom Patrol, Season 2 PremiereEsme & Roy, Season 2A PremiereSearch Party, Season 3 Premiere

June 26Hormigas (AKA The Awakening of the Ants), 2020

June 27Doctor Sleep (Directors Cut), 2020 (HBO)

June 28Ill Be Gone in the Dark, Docuseries Premiere (HBO)

June 30Welcome to Chechnya, Documentary Premiere (HBO)

Summer is less than a month away and with everyone staying at home as much as possible to prevent the spread of COVID-19, were imagining your plans for June, July and August have more to do with TV listings than usual. Luckily, dozens of new and returning shows are premiering this summer, even though there are fewer than usual due to pandemic-forced production shutdowns. But the list still includes some big titles like The Twilight Zone and The Umbrella Academy, plus original shows for upcoming streaming services HBO Max and Peacock. Click through TheWraps gallery to see which series will be premiering this summer and when.

Also Read: Fall TV 2020: Every Broadcast Show Canceled, Renewed and Ordered So Far (Updating)

Series:NOS4A2 Net: AMC/BBC America Premiere Date: Sunday, June 21 Time: 9 p.m.

Series: Perry Mason Net: HBO Premiere Date: Sunday, June 21 Time: 9 p.m.

Series:Yellowstone Net: Paramount Network Premiere Date: Sunday, June 21 Time: 9 p.m.

Series: Greenleaf Net: OWN Premiere Date: Tuesday, June 23 Time: 9 p.m.

Series: Doom Patrol Net: HBO Max/DC Universe Premiere Date: Thursday, June 25 Time: N/A

Series: Search Party Net: HBO Max Premiere Date: Thursday, June 25 Time: N/A

Series: The Twilight Zone Net: CBS All Access Premiere Date: Thursday, June 25 Time: N/A

Series: Black Monday Net: Showtime Premiere Date: Sunday, June 28 Time: 8 p.m.

Series: Ill Be Gone in the Dark Net: HBO Premiere Date: Sunday, June 28 Time: 10 p.m.

Series: Marriage Boot Camp Net: We TV Premiere Date: Thursday, July 2 Time: 9 p.m.

Series: The Baby-Sitters Club Net: Netflix Premiere Date: Friday, July 3 Time: N/A

Series: Hanna Net: Amazon Prime Video Premiere Date: Friday, July 3 Time: N/A

Series: Outcry Net: Showtime Premiere Date: Sunday, July 5 Time: 10 p.m.

Series: Tough as Nails Net: CBS Premiere Date: Wednesday, July 8 Time: 9 p.m.

Series: Close Enough Net: HBO Max Premiere Date: Thursday, July 9 Time: N/A

Series: Expecting Amy Net: HBO Max Premiere Date: Thursday, July 9 Time: N/A

Series: Greatness Code Net: Apple TV+ Premiere Date: Friday, July 10 Time: N/A

Series: "Little Voice" Net: Apple TV+ Premiere Date: Friday, July 10 Time: N/A

Series: P-Valley Net: Starz Premiere Date: Sunday, July 12 Time: 8 p.m.

Series: Brave New World Net: Peacock Premiere Date: Wednesday, July 15 Time: N/A

Series: The Capture Net: Peacock Premiere Date: Wednesday, July 15 Time: N/A

Series: In Deep With Ryan Lochte Net: Peacock Premiere Date: Wednesday, July 15 Time: N/A

Series: Intelligence Net: Peacock Premiere Date: Wednesday, July 15 Time: N/A

Series: The House of Ho Net: HBO Max Premiere Date: Thursday, July 16 Time: N/A

Series: Room 104 Net: HBO Premiere Date: Friday, July 24 Time: 11 p.m.

Series: "The Alienist: Angel of Darkness" Net: TNT Premiere Date: Sunday, July 26 Time: 9 p.m.

Series: The Dog House" Net: HBO Max Premiere Date: Thursday, July 30 Time: N/A

Series: The Frayed Net: HBO Max Premiere Date: Thursday, July 30 Time: N/A

Series: Muppets Now Net: Disney+ Premiere Date: Friday, July 31 Time: N/A

Series: The Umbrella Academy Net: Netflix Premiere Date: Friday, July 31 Time: N/A

Series: "Selling Sunset" Net: Netflix Premiere Date: Friday, Aug. 7 Time: N/A

Series: The Good Lord Bird Net: Showtime Premiere Date: Sunday, Aug. 9 Time: 10 p.m.

Series: Love Fraud Net: Showtime Premiere Date: Sunday, Aug. 30 Time: 9 p.m.

Heres when 34 broadcast, cable and streaming series debut and come back

Summer is less than a month away and with everyone staying at home as much as possible to prevent the spread of COVID-19, were imagining your plans for June, July and August have more to do with TV listings than usual. Luckily, dozens of new and returning shows are premiering this summer, even though there are fewer than usual due to pandemic-forced production shutdowns. But the list still includes some big titles like The Twilight Zone and The Umbrella Academy, plus original shows for upcoming streaming services HBO Max and Peacock. Click through TheWraps gallery to see which series will be premiering this summer and when.

Also Read: Fall TV 2020: Every Broadcast Show Canceled, Renewed and Ordered So Far (Updating)

Read more here:

Heres Everything Coming to HBO Max in June - TheWrap

New method provides unique insight into the development of the human brain – Science Codex

Stem cell researchers at Lund University in Sweden have developed a new research model of the early embryonic brain. The aim of the model is to study the very earliest stages of brain to understand how different regions in the brain are formed during embryonic development. With this new insight, researchers hope to be able to produce different types of neural cells for the treatment of neurological diseases more efficiently. The study is published in the journal Nature Biotechnology.

In order to develop stem cell treatments for neurological diseases such as Parkinson's Disease, epilepsy and stroke, researchers must first understand how the human brain develops in the embryonic stage. With knowledge of how neural cells are formed at different developmental stages, researchers have the opportunity to develop new stem cell therapies more quickly in the laboratory.

"The challenge is that there are thousands of different sub-types of neural cells in the human brain, and for each disease we need to be able to produce exactly the right type of neural cell", says Agnete Kirkeby, researcher at the Wallenberg Centre for Molecular Medicine and the Department of Experimental Medical Science at Lund University.

Studies on how each individual neural cell forms in the embryo during brain development are essential for the researchers to be able to understand how to produce these specific cells in the laboratory.

Research on the early development of the human brain, from five days after the fertilisation of the cell to approximately seven weeks, have so far been difficult as researchers have not had access to human embryonic tissue from these early stages of development. Therefore, nearly all knowledge of the earliest development of the brain is based on studies in flies, chickens and mice.

"However, the composition of the human brain differs greatly from the animals' brains. Therefore, this period in the development of the human brain has long been viewed as the black box of neurology", says Agnete Kirkeby.

Together with colleagues from the University of Copenhagen and bioengineers Thomas Laurell and Marc Isaksson from the Faculty of Engineering at Lund University, Agnete and her team have now created a model that mimics the early developmentalstages of the human brain through the use of stem cells. The stem cells are cultivated in a custom-built cell culture chamber where they are exposed to an environment which resembles the environment in the early embryonic brain.

"In the laboratory model called MiSTR (Microfluidic-controlled Stem cell Regionalisation), we can create tissue that contains different brain regions next to each other, similar to an embryonic brain approximately four to five weeks after fertilisation."

"We start with a small group of cells that will form the brain and instruct the cells by exposing them to a gradient of a specific growth factor (WNT) so that they form different regions of the brain. Our model is better than previously published models because it is much more reproducible and contains more brain regions. We can now use it to study unknown characteristics in the early development of the human brain", explains Agnete Kirkeby.

Agnete Kirkeby believes that the new method may be used to investigate how brain cells in the early embryonic stages react to certain chemicals surrounding us in our daily lives

"This is a significant step forward for stem cell research. For the first time, we now have access to tissue that resembles the early embryonic brain and can therefore study processes behind brain development in a way that has not been possible before. We can for instance use it for testing how chemical substances in our environment might impact on embryonic brain development." explains Kirkeby.

Another aim for the future is to use the model to create a complete map of the development of the human brain. This will help to speed up the development of new stem cell treatments for neurological diseases.

"Once we have the map we will also become better at producing human neural cells in the laboratory that could be used for transplantations, regenerative therapy and to study the brain's function as well as different disease states. . It took us ten years to develop a stem cell treatment for Parkinson's disease because our methods were dependent on trial and error. Our goal is that this process will be much faster in the future for other diseases", concludes Agnete Kirkeby.

Continue reading here:

New method provides unique insight into the development of the human brain - Science Codex

Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19…

ROCKVILLE, Md., May 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC) and Myriad Genetics Inc. (NASDAQ: MYGN) today announced that levels of novel cytokine, LIGHT, were highly correlated with disease severity and mortality in a COVID-19 acute respiratory distress syndrome (ARDS) biomarker study. The biomarker study was conducted using the serum samples of 47 hospitalized COVID-19 patients and 30 healthy controls from Hackensack Meridian Health Network.

In April 2020, approximately 1,500 people in the United States died each day from COVID-19. The viral infection triggers a hyperactive immune response leading to cytokine storm and Acute Respiratory Distress Syndrome (ARDS), which is a leading cause of death in patients who die of COVID-19. Although this hyperinflammatory process is poorly understood, the data from this study implicates the inflammatory cytokine, LIGHT, as a potential key driver of cytokine storm leading to ARDS and death.

LIGHT levels were significantly elevated in the serum of hospitalized patients with COVID-19 versus healthy controls (p value < 0.0001). The highest LIGHT levels were found in patients who required ventilator support, particularly in patients over 60. Importantly, the data demonstrated elevated LIGHT levels were also strongly linked with mortality (p=0.02).

Dr. David Perlin, Ph.D., chief scientific officer, senior vice president of the Center for Discovery and Innovation, and Professor of Medical Sciences at the Hackensack Meridian School of Medicine at Seton Hall University, commented These data are compelling and demonstrate that the inflammatory cytokine LIGHT may play a key role in cytokine storm associated with COVID-19 ARDS that leads to increased morbidity and mortality. Reducing LIGHT levels might be a key to dampening the cytokine storm in these patients, preventing the need for ventilator support and reducing mortality.

Dr. Garry Neil, M.D. chief scientific officer, Cerecor commented, As a company, we recognized the impact of cytokine storm-induced ARDS and the need for treatment options for patients in this area of high unmet need. We remain focused on the CERC-002 clinical program and rapidly moving it forward for the treatment of cytokine storm induced ARDS.

Role of LIGHT in Acute Inflammatory Response

LIGHT (homologous to Lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes) is a cytokine with inflammatory actions encoded by the TNFSF14 gene. LIGHT has been shown to play a key role in the immune response to viral pneumonia. LIGHT plays an important role in regulating immune responses in the lung, gut and skin. It stimulates T Cell and B Cell response as well as induces the release of other cytokines such as IL1, IL6, IL-8, IL-10, TNF and GM-CSF.

CERC-002 (anti-LIGHT monoclonal antibody)

CERC-002 is a fully human monoclonal antibody with neutralizing action against LIGHT (TNFSF14), for treatment of children with Pediatric Crohns Disease. Cerecor holds an open IND with FDA and the drug is currently being studied in a Phase I clinical trial for patients with refractory severe Crohns disease, currently not recruiting due to COVID-19.

Free LIGHT Assay from Myriad RBM

Myriad RBM, a subsidiary of Myriad Genetics, Inc., in collaboration with Cerecor has developed an ultrasensitive assay for the detection of free LIGHT. The assay is validated for serum or plasma samples and has sufficient sensitivity to reliably measure LIGHT from normal and disease subjects.

About Myriad

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

About Hackensack Meridian Health

Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care. Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two children's hospitals - Joseph M. Sanzari Children's Hospital in Hackensack, K. Hovnanian Children's Hospital in Neptune; nine community hospitals Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital Carrier Clinic in Belle Mead; and two rehabilitation hospitals JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick. Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 34,100 team members, and 6,500 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.

About the Center for Discovery and Innovation

The Center for Discovery and Innovation (CDI), a newly established member of Hackensack Meridian Health, seeks to translate current innovations in science to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions. The CDI, housed in a fully renovated state-of-the-art facility, offers world-class researchers a support infrastructure and culture of discovery that promotes science innovation and rapid translation to the clinic.

About Cerecor

Cerecor is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases. The Company is advancing an emerging clinical-stage pipeline of innovative therapies. The Companys pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation (ODD) to all three CERC-800 programs, thus potentially qualifying the Company to receive a Priority Review Voucher (PRV) upon approval of a new drug application (NDA). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody being developed for the treatment of autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma (MM). CERC-006 is a dual mTOR inhibitor being developed for the treatment of complex Lymphatic Malformations. CERC-002 is an anti-LIGHT monoclonal antibody being developed for the treatment of Pediatric-onset Crohns Disease.

For more information about Cerecor, please visit http://www.cerecor.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Cerecors control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Cerecors plans, objectives, projections, expectations and intentions and other statements identified by words such as projects, may, might, will, could, would, should, continue, seeks, aims, predicts, believes, expects, anticipates, estimates, intends, plans, potential, or similar expressions (including their use in the negative), or by discussions of future matters such as: the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Cerecors management but are subject to significant risks and uncertainties, including: drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; regulatory risks; Cerecor's cash position and the need for it to raise additional capital; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic; and those other risks detailed in Cerecors filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Cerecor expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Cerecors expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries for Cerecor, Inc.

James Harrell,Investor RelationsChief Commercial OfficerCerecor Inc.jharrell@cerecor.com623.439.2220 office

For media and investor inquiries for Myriad Genetics, Inc.

Scott GleasonSVP of Investor Relations and Corporate StrategyMyriad Genetics, Inc.sgleason@myriad.com801.584.1143 office

Read more from the original source:

Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19...

Importance of Biopsy and Tissue Analysis in Oncology – Patch.com

Why is tumor tissue so important in the management of cancer patients? It turns out it goes well beyond establishing a diagnosis.

The purpose of obtaining tissue from a tumor through a biopsy has evolved over the last few years from merely establishing a diagnosis to predicting response to therapy and providing a realistic prognosis for patients. This evolution stems from the recently acquired ability to precisely analyze tissue using molecular assays, biomarkers and genotyping and is in keeping with the notion of "molecular medicine" itself often referred to as "personalized or precision medicine" where a treatment plan is formulated based on the specific characteristics of a patient's tumor. Indeed, patients and physicians alike want to know the status of a tumor from a molecular point of view in order to identify potential targets within this tumor for drug therapy and suggest available drug options. In this manner, a "personalized" treatment plan can be formulated based on realistic expectations, making the need for tissue in the first place absolutely critical.

Cancer is not a static process which means that tissues samples are required throughout the lifetime of the tumor; from the initial diagnosis until the tumor is entirely destroyed. Obtaining samples at multiple time points has now become an essential component of the management of cancer patients to monitor the evolution of a specific tumor and assess real-time the molecular signature of a tumor. In addition, tumors are notoriously heterogeneous not only across sites of metastases but also within a single tumor making it very difficult to obtain a global picture of the tumor from its molecular characteristics. Therefore, multiple samples in various locations are often necessary for molecular profiling, help select a treatment option and assess tumor resistance. Fortunately, constant progress made in imaging technology allows for extremely precise visualization of tumors, targeting and sample collection. A tumor can now be sampled at its core, rim or anywhere in between. Such percutaneously obtained tumor samples have become standard of care for cancer patients.

Identifying mutations that can be targeted with drugs is key to being able to provide a treatment plan for patients, especially in view of the recent shift away from conventional chemotherapy to the newer targeted drugs capable of inhibiting specific pathways that are unregulated or simply "present" in cancer cells (EGFR, ALK, VEGF, BRCA and more recently PD-1, PD-L1 and CTLA-4 to name a few). Genomic profiling has also become indispensable in the conduct of clinical trials where the identification of specific biomarkers is often required before a patient can be enrolled in a study. Such predictive biomarkers can also streamline drug development by allowing to design smaller clinical trials focused on treating tumors that have a common biologic signature. Such an approach could possibly do away with the large clinical trials typical of an old era where the anatomic location of a tumor was more important than its biologically-based targets.

We have come a long way since a needle was inserted into a tumor to obtain a diagnosis. From diagnosis to molecular profiling, tumor resistance and biomarkers of response, the need for tumor tissue in the management of cancer patients has become absolutely indispensable. As a result, the role of imaging to guide such biopsy procedures will only grow since precision to obtain tumor samples is paramount. In the end, cancer patients will be better served and the era of "personalized medicine" will truly be here to stay.

This blog was originally published on Jeff Geschwind's website.

View original post here:

Importance of Biopsy and Tissue Analysis in Oncology - Patch.com

Progenity Adds Operational Expertise to Leadership Team with Appointment of Damon Silvestry as COO – Business Wire

SAN DIEGO--(BUSINESS WIRE)--Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the appointment of Damon Silvestry as Chief Operating Officer (COO). With over 15 years of strategic lab and business operations experience, Mr. Silvestry will oversee key business functions with the goal of delivering operational excellence, coordinating product teams to achieve ambitious growth targets, and driving the companys service culture.

Damon strengthens the Progenity executive team with an established track record as a results-driven leader capable of influencing excellence in people, process, and products while sustaining focus on cost, efficiency, margin improvement, compliance, and a positive payor/customer experience, said Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity. We are focused on accelerating growth and creating an outstanding user experience within our diagnostic offerings and therapeutic precision medicine platforms. Damons experience in leading organizations, scaling similar businesses whilst improving payor and customer service standards, will enable us to achieve our goal of delivering a robust pipeline of digital health solutions based on transformative innovation.

Mr. Silvestry combines a deep understanding of the genetic testing landscape with experience managing organizational change in high-growth life science and technology companies, including roles with Natera, Miraca Life Sciences, and Dell. Most recently, Mr. Silvestry served as Senior Vice President, Operations and People Office at Natera, where he led a team of more than 350 members to deliver both genetic testing and liquid biopsy services to enable earlier detection of cancer and determine optimal treatments.

Its imperative that Progenity is positioned to successfully drive improvement of patient outcomes in prenatal and perinatal medicine, oncology, and gastroenterology, said Mr. Silvestry. I look forward to leading Progenitys operations and client services teams through continual improvement of operational excellence.

About Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenitys vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For more information on how Progenity is helping clinicians and patients prepare for life, please visit http://www.progenity.com.

Read the original:

Progenity Adds Operational Expertise to Leadership Team with Appointment of Damon Silvestry as COO - Business Wire

Why Portugal’s Covid-19 test rate is more than double almost every other nation – Telegraph.co.uk

While in the UK the NHS kept tight control of testing until recently, the Portuguese government quickly realised spreading the load was the answer.

As recently as May 1 to 17, non-state labs were still responsible for more than half of the almost 14,000 tests being conducted daily.

But the roots of Portugals world-class Covid-19 testing regime began much earlier.According to Our World in Data whose testing rates have been cited by the OECD and others Portugal has been among the top 10 countries in the world for testing per capita since mid-April.

On Friday, Denmark (with a GDP per capita 2.7 times that of Portugal) and Lithuania (with a similar GDP per capita to Portugal) were the only nations of more than 2 million people with a higher testing rate.

Like most countries, Portugals initial testing efforts started slowly amid difficulties securing kits in a ferocious global market.

The stress initially was to provide testing, said biology professor Miguel Viveiros, deputy director of IMHT.

We were not prepared for testing in quantity for the speed of transmission. In early March, Portugal was testing less per capita than the UK and much of Europe.

Professor Maria Manuel Mota, director of the institute of molecular medicine at the University of Lisbon, was speaking to doctors at the large university hospital on campus. They were worried about having enough tests to make sure the disease wasnt spreading rapidly in the medical community, let alone for the wider population.

Obviously there will be no testing for everyone, they told her. It is a difficult test, it takes a few hours, you know, it's expensive.

Sitting at home on March 11, Professor Mota quickly discovered that didnt have to be the case, thanks to her institutes experience with PCR-based tests for malaria.

The test we do all the time in almost every single lab in our institute is PCR, so it should not be difficult, she remembered thinking. Instead of relying on expensive kits that come from abroad we could design something.

To lead the project, she called on researcher Vanessa Zuzarte Lus, who had a potential testing protocol in mind within a few hours. The next day they were speaking to a Portuguese company about manufacturing the reagents needed for the tests, one factor UK authorities blamed for testing difficulties.

They were ready and working within a week, leaving only accreditation from the Dr Ricardo Jorge National Institute of Health left to secure.

The Portuguese authorities were fantastic, Professor Mota said. As soon as I called the right people they told us okay, let's validate this together. The accreditation process ran smoothly and the tests were being rolled out to nursing homes by the end of March.

Within two or three weeks, university labs and private institutes across Portugal were using the protocol developed at IMM, or developing their own, to bolster public testing efforts.

In the UK, independent labs trying to take similar steps were still complaining their offers to help were being ignored as late as April 10, well after health secretary Matt Hancock set a target of 100,000 tests a day.

Follow this link:

Why Portugal's Covid-19 test rate is more than double almost every other nation - Telegraph.co.uk

Couple on the coronavirus front lines – UCI News

Naptime is over.

Ilhem Messaoudi Powers, associate professor of molecular biology & biochemistry at UCI, is enjoying a rare weekend at home with her husband, Dr. Michael Powers, when they hear the rustling of their two young children.

He bounds up the stairs to retrieve Owen, 3, and Olivia, 6 months, from a Saturday afternoon slumber. Soon the living room is full of the joyous noises of a toddler and an infant.

When theyre not wearing their mommy and daddy hats, Ilhem and Michael Powers are exploring and immersing themselves in an entirely different world: the COVID-19 pandemic.

A virologist and immunologist, Ilhem Powers leads a team of researchers whove launched a surveillance study of UCI Health workers to determine how many have antibodies against the coronavirus.

Michael Powers is a pulmonologist who works as a critical care doctor at the Naval Medical Center San Diego, caring for patients with COVID-19, as well as others.

Because of his unpredictable schedule, he often stays for days at an apartment in San Diego while his wife, with the assistance of a part-time nanny, juggles kids and career from the couples on-campus home and her laboratory.

Mike and I have been through a lot together, she says. Weve really learned to focus on the now.

Indeed, her husband was just two weeks into medical school at New Orleans Tulane University when Hurricane Katrina hit in late August of 2005. Ilhem Powers had accepted a job at the school as an assistant professor and was getting ready to relocate from their previous home in Portland, Oregon.

The New Orleans duplex that the couple had renovated with most of their savings wound up under 8 feet of water. It took them more than a year to recover.

One of the biggest lessons Ive learned in life is to focus on the things you have some control over, Michael Powers says. You just have to let go of the rest.

Surveillance study

Ilhem Powers lab cohort have pivoted from their usual work to conduct COVID-19 research as members of UCIs Institute for Immunology and Center for Virus Research.

Their surveillance study, funded by a $60,000 UCI grant and expected to last a year, will repeatedly examine 300 healthcare providers. The collection of samples has already begun.

We want to know how many of them may have already been exposed [to COVID-19] and didnt know about it and how many of them potentially have immunity, Ilhem Powers says. Well take blood samples and nose swabs to measure antibodies and T cell responses, which kill infected cells, as well as potential asymptomatic shedding. Its a multipronged approach.

Arriving at UCI in January 2017 after serving as a researcher and assistant professor at UC Riversides School of Medicine, she has years of experience studying how the human immune system interacts with emerging viral diseases such as Ebola, Chikungunya, Zika and monkeypox.

For some viruses, Ilhem Powers explains, antibodies are sufficient [to kill them]. For others, you need more of a T cell response. We dont yet know enough about this novel coronavirus.

More community surveillance needs to be done, she says: How many people have potential COVID-19 antibodies? We also need to look at the immune response in patients those currently in hospitals and then determine the difference between the immune response of those who end up in the ICU versus those who end up being sent home.

Health scare

Michael Powers, who began his residency at the Naval Medical Center San Diego in 2010, says the COVID-19 pandemic has forced him and other doctors to live with a lot of uncertainty.

But he has a stoic air about him despite his relatively new role of treating patients with a little-understood disease. Perhaps experiencing a serious lung-related health scare himself contributes to his even-keeled nature.

During his wifes last year at UC Riverside, Michael Powers went on an outreach mission to Ghana. Shortly after returning home, he developed MRSA in his lungs and had to undergo thoracic surgery. He spent 10 days in the hospital and 30 days in convalescence.

It was a pulmonologists worst nightmare, Ilhem Powers says. It was really scary.

So is COVID-19, her husband says: I think a lot of people have a very romanticized notion of what ICU-level care is and being on a ventilator. The movies definitely dont do it justice.

When people go on ventilators, its not at all uncommon for them to be on them for two weeks or more. Its not a pleasant thing to have a giant plastic tube down your throat and a machine telling you when to breathe.

Enjoying the little moments

Michael Powers says he takes extreme precautions at work and elsewhere in San Diego before driving up to Irvine to spend time with his wife and children.

People ask me all the time, Isnt he worried? Ilhem Powers says. They ask, Shouldnt he just stay in his apartment and not come up here and pose a health risk to you and your kids? And we just say we understand and accept the risk.

She and her colleagues get tested regularly for COVID-19 using equipment in their lab.

Having already weathered a lot of adversity, the couple believe theyre uniquely equipped to cope with COVID-19.

What we both do for a living, and our past experience dealing with crises, has put us in this perfect position to deal with this pandemic, he says.

For many people, she adds, this is the first time that things outside their control have completely dominated their life.

Often, the two will sit down and go over COVID-19 research papers together and compare notes, discussing where the pandemic is headed, possible therapies and longer term potential vaccines.

But they make sure that when theyre together, they shower most of their attention on Owen and Olivia.

When hes home, Ilhem Powers says of her husband, its family time. For us, its all about enjoying the little moments.

View post:

Couple on the coronavirus front lines - UCI News

Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple…

DetailsCategory: AntibodiesPublished on Wednesday, 27 May 2020 10:50Hits: 80

BASEL, Switzerland I May 27, 2020 I Novartis announced today that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th Congress of the European Academy of Neurology (EAN). The data continue to demonstrate ofatumumab (OMB157) as a potential novel treatment option for patients with RMS. The safety profile was comparable to teriflunomide2.

Ofatumumab is a targeted B-cell therapy that, if approved, addresses a clinical unmet need as the first B-cell therapy that can be self-administered at home through an autoinjector pen2. In addition to being presented virtually, the data were also published in the European Journal of Neurology, Volume 27, Supplement 1, May 2020.

A post hoc analysis from the Phase III ASCLEPIOS I and II trials (n=1882) assessed the odds of patients achieving NEDA-3 with ofatumumab versus teriflunomide within the first (Month 012) and second year (Month 1224) of treatment1. NEDA-3 is a comprehensive composite measure commonly used to assess treatment outcomes in patients with RMS. It is defined as an absence of three measures of disease activity: relapses; disease progression, measured as 6-month confirmed disability worsening (CDW), and gadolinium enhancing (Gd+) T1 lesions3. The study results showed that compared with teriflunomide, a greater proportion of patients treated with ofatumumab achieved NEDA-3 in year 1 (47.0% vs 24.5%; P<.001) and in year 2 (87.8% vs 48.2%; P<.001)1.

Achieving no evidence of disease activity is widely recognized as an important treatment goal for multiple sclerosis therapies, said Professor Ludwig Kappos, University Hospital Basel. These data suggest that halting new disease activity is possible by targeted B-cell therapy in RMS.

A separate analysis from the APLIOS trial (n=284) showed ofatumumab treatment led to rapid and sustained depletion of both CD20+B- and T-cells in patients with RMS. Ofatumumab depleted different B- and T-cell subsets including memory B-cells and nave B-cells, as well as a subset of T-cells that are known to exhibit an activated phenotype. However, CD3+T-cells that do not express the CD20 receptor, were largely unaffected4.

These results are encouraging and support our belief that, if approved, ofatumumab could have the potential to significantly improve the lives of people with RMS, said Krishnan Ramanathan, Neuroscience Global Program Head at Novartis. These data are a testament to our commitment to reimagining medicine and advancing innovative treatments that help people with this serious and progressive disease.

Regulatory action for ofatumumab in the US is expected in June 2020. Novartis is committed to bringing ofatumumab to patients around the world, and additional regulatory filings are currently under way.

About ofatumumabOfatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) in development for RMS that is self-adminstered by a once-monthly injection, delivered subcutaneously2,5. As shown in preclinical studies, ofatumumab is thought to work by binding to a distinct epitope on the CD20 molecule inducing potent B-cell lysis and depletion6. The selective mechanism of action and subcutaneous administration of ofatumumab allows precise delivery to the lymph nodes, where B-cell depletion in MS is needed, and may preserve the B-cells in the spleen, as shown in preclinical studies7. Once-monthly dosing of ofatumumab also allows fast repletion of B-cells and offers more flexibility8. Ofatumumab was originated by Genmab and licensed to GlaxoSmithKline; Novartis obtained rights for ofatumumab from GlaxoSmithKline in all indications, including RMS, in December 20159.

About ASCLEPIOS I and II studiesThe ASCLEPIOS I and II studies are twin, identical design, flexible duration (up to 30 months), double-blind, randomized, multi-center Phase III studies evaluating the safety and efficacy of ofatumumab 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with RMS. The ASCLEPIOS I and II studies enrolled 1882 patients with MS, between the ages of 18 and 55 years, with an Expanded Disability Status Scale (EDSS) score between 0 and 5.52. The studies were conducted in over 350 sites in 37 countries10. Ofatumumab demonstrated a significant reduction in annualized relapse rate (ARR) by 50.5% (0.11 vs 0.22) and 58.5% (0.10 vs 0.25) compared with teriflunomide (P<.001 in both studies) in ASCLEPIOS I and II respectively (primary endpoint). Ofatumumab showed significant reduction of both Gd+T1 lesions and new or enlarging T2 lesions. It significantly reduced the mean number of both Gd+T1 lesions (97.5% and 93.8% relative reduction in ASCLEPIOS I and II, respectively, both P<.001) and new or enlarging T2 lesions (82.0% and 84.5% relative reduction in ASCLEPIOS I and II, respectively, (both P<.001).

Ofatumumab also showed a relative risk reduction of 34.4% (P=.002) in 3-month CDW and 32.5% (P=.012) in 6-month CDW compared with teriflunomide in pre-specified meta-analysis, as defined in ASCLEPIOS. Ofatumumab demonstrated that it lowered neurofilament light levels in serum at the first assessment at Month 3 compared with teriflunomide. There was no difference in slope of brain volume change from baseline between treatments. In a measure of 6-month confirmed disability improvement events, a favorable trend was seen but this did not reach significance. The frequency of serious infections and malignancies was similar across both treatment groups, and overall, ofatumumab had a similar safety profile to teriflunomide. Injection-related reactions, injection-site reactions and upper respiratory tract infection were the most commonly observed adverse events across both treatment groups, occurring in 10% of patients2.

A separate post hoc analysis demonstrated ofatumumab may halt new disease activityin RMS patients. It showed the odds of achieving NEDA-3 (no relapses, no MRI lesions, and no disability worsening combined) with ofatumumab versus teriflunomide were >3-fold higher at Month (M) 012 (47.0% vs 24.5% of patients; P<.001) and >8-fold higher at M1224 (87.8% vs 48.2% of patients; P<.001)1. Overall ofatumumab, a fully human antibody targeting CD20+ B-cells, delivered superior efficacy and demonstrated a safety and tolerability profile with infection rates similar to teriflunomide2.

About APLIOS studyThe APLIOS study is a 12-week, open-label, Phase II bioequivalence study to determine the onset of B-cell depletion with ofatumumab subcutaneous monthly injections and the bioequivalence of subcutaneous administration of ofatumumab via a pre-filled syringeas used in ASCLEPIOS I and IIand an autoinjector pen in patients with RMS. Patients were randomized according to injection device and site including the abdomen and the thigh. B-cell depletion was measured nine times over 12 weeks and Gd+ lesion counts were assessed at baseline and at Weeks 4, 8 and 12. Regardless of injection device or site, ofatumumab 20 mg subcutaneous monthly injections resulted in rapid, close to complete and sustained B-cell depletion. The proportion of patients with B-cell concentrations of <10 cells/L was >65% after the first injection by Day 7, 94% by Week 4 and sustained >95% at all following injections. Ofatumumab treatment reduced the mean number of Gd+lesions from baseline (1.5) to 0.8, 0.3 and 0.1 by Weeks 4, 8 and 12, respectively. The proportion of patients free from Gd+ lesions at the corresponding time points were 66.5%, 86.7%, and 94.1%, respectively4,5.

About Multiple Sclerosis MS disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss11. MS, which affects approximately 2.3 million people worldwide12, is often characterized into three forms: primary progressive MS (PPMS)13, relapsing remitting MS (RRMS), and secondary progressive MS (SPMS), which follows from an initial RRMS course and is characterized by physical and cognitive changes over time, in presence or absence of relapses, leading to a progressive accumulation of neurological disability14. Approximately 85% of patients initially present with relapsing forms of MS12.

Novartis in NeuroscienceNovartis has a strong ongoing commitment to neuroscience and to bringing innovative treatments to patients suffering from neurological conditions where there is a high unmet need. We are committed to supporting patients and physicians in multiple disease areas, including MS, migraine, Alzheimer's disease, Parkinson's disease, epilepsy and attention deficit hyperactivity disorder, and have a promising pipeline in MS, Alzheimer's disease, spinal muscular atrophy and specialty neurology.

About NovartisNovartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more athttps://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnewsFor Novartis multimedia content, please visit https://www.novartis.com/news/media-libraryFor questions about the site or required registration, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

References1. Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis: Analysis of no evidence of disease activity (NEDA-3) from ASCLEPIOS I and II trials. Eur J Neurol. 2020;27(1):261263.2. Hauser S. Efficacy and safety of ofatumumab versus teriflunomide in relapsing multiple sclerosis: results of the phase 3 ASCLEPIOS I and II trials. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Conference; September 1113, 2019; Stockholm, Sweden.3. MS Trust. NEDA (no evidence of disease activity) [online]. Available from: https://www.mstrust.org.uk/a-z/neda-no-evidence-disease-activity [Last accessed: May 2020].4. Wiendl H, Fox E, Goodyear A, et al. Effect of Subcutaneous Ofatumumab on Lymphocyte Subsets in Patients with RMS: Analysis from the APLIOS Study. Eur J Neurol. 2020;27(1).5. Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell Depletion with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Results from the APLIOS Bioequivalence Study. Presented at Americas Committee for Treatment and Research in Multiple Sclerosis Forum; February 2729, 2020.6. Smith P, Kakarieka A, Wallstroem E. Ofatumumab is a fully human anti-CD20 antibody achieving potent B-cell depletion through binding a distinct epitope. Poster presented at ECTRIMS; September 2016; London, UK.7. Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity. Poster presented at ECTRIMS; September 1417, 2016; London, UK.8. Savelieva M, Kahn J, Bagger M, et al. Comparison of the B-Cell Recovery Time Following Discontinuation of Anti-CD20 Therapies. ePoster presented at ECTRIMS; October 2528, 2017; Paris, France.9. GSK press release. GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis. December 21, 2015. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-rights-to-ofatumumab-for-auto-immune-indications-to-novartis/ [Last accessed: May 2020].10. Kappos L, Bar-Or A, Comi G, et al. Ofatumumab Versus Teriflunomide in Relapsing Multiple Sclerosis: Baseline Characteristics of Two Pivotal Phase 3 Trials (ASCLEPIOS I and ASCLEPIOS II). Poster presented at ECTRIMS; October 1012, 2018; Berlin, Germany.11. National Multiple Sclerosis Society. Definition of MS. Available from: https://www.nationalmssociety.org/What-is-MS/Definition-of-MS [Last accessed: May 2020].12. Multiple Sclerosis International Federation. Atlas of MS 2013. Mapping Multiple Sclerosis Around the World. Available from: http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf [Last accessed: May 2020].13. MS Society. Types of MS. Available from: https://www.mssociety.org.uk/about-ms/types-of-ms [Last accessed: May 2020].14. National Multiple Sclerosis Society. Secondary Progressive MS (SPMS). Available from: https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS [Last accessed: May 2020].

SOURCE: Novartis

See original here:

Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple...

Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 b | DDDT – Dove Medical Press

Peng Gao,1,2 Shuo Shen,1,2 Xiaodong Li,3 Dandan Liu,1,2 Yuqing Meng,1,2 Yanqing Liu,1,2 Yongping Zhu,1,2 Junzhe Zhang,1,2 Piao Luo,1,2 Liwei Gu1,2

1Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, Peoples Republic of China; 2Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, Peoples Republic of China; 3Institute of Chinese Materia Medica, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, Peoples Republic of China

Correspondence: Liwei Gu Email lwgu@icmm.ac.cn

Background: Leukemia threatens so many lives around the world. Dihydroartemisinin (DHA), as a typical derivative of artemisinin (ART), can efficiently inhibit leukemia, but the controversial mechanisms are still controversial. Many reports showed that tumor cells acquire energy through the glycolysis pathway, pyruvate kinase M2 (PKM2) plays a crucial role in regulating glycolysis. However, it is unclear whether PKM2 or other key molecules are involved in DHA induced cytotoxicity in leukemia cells. Thus, this paper systematically investigated the anticancer effect and mechanism of DHA on human chronic myeloid leukemia K562 cells.Methods: In vitro, cytotoxicity was detected with CCK-8. Glucose uptake, lactate production and pyruvate kinase activity were investigated to evaluate the effect of DHA on K562 cells. To elucidate the cellular metabolism alterations induced by DHA, the extracellular acidification rate was assessed using Seahorse XF96 extracellular flux analyzer. Immunofluorescence, real-time PCR, and Western blotting were used to investigate the molecular mechanism.Results: We found that DHA prevented cell proliferation in K562 cells through inhibiting aerobic glycolysis. Lactate product and glucose uptake were inhibited after DHA treatment. Results showed that DHA modulates glucose uptake through downregulating glucose transporter 1 (GLUT1) in both gene and protein levels. The cytotoxicity of DHA on K562 cells was significantly reversed by PKM2 agonist DASA-58. Pyruvate kinase activity was significantly reduced after DHA treatment, decreased expression of PKM2 was confirmed in situ.Conclusion: The present study implicated that DHA inhibits leukemia cell proliferation by regulating glycolysis and metabolism, which mediated by downregulating PKM2 and GLUT1 expression. Our finding might enrich the artemisinins antitumor mechanisms.

Keywords: tumor, leukemia, glycolysis, DHA, PKM2, GLUT1

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more from the original source:

Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 b | DDDT - Dove Medical Press

When will prosecutors identify and compensate overseas victims of corruption? – The FCPA Blog

Identifying and compensating overseas victims of corruption is a major challenge that prosecutors have yet to adequately address. AsJeffrey Kaplan recently discussed in a post for the FCPA Blog, when corruption is treated as victimless, it may allow those involved in the crime to feel comfortable with their participation.

Despite an undeniable rise in the global will to prosecute international corruption and overseas bribery, seldom do law enforcement agencies return funds to the victims of the corrupt scheme. In 2011, the United Kingdom introduced criminal infractions with the adoption of theBribery Act. However, since its enactment, prosecutors have only sought 33 million ($40 million) in compensation from a total of 602 million ($736 million) secured through sanctions or settlements, representing less than 6 percent of the total sum levied. Why has there been so little compensation to those directly affected?

Our recent fieldwork in the Democratic Republic of Congo clearly demonstrates thedevastating impactof corruption on the lives of tens of thousands of local residents directly affected at just one cobalt mine the KMT mine (now called Metalkol RTR) in Kolwezi, a rich copper and cobalt tailings site considered one of the crown jewels of Congos mining assets.

The abrupt closure of the KMT mine in 2009 due to corruption resulted in 700 workers losing their jobs and corresponding benefits, and severely affected an estimated 32,000 Congolese residents who were deprived of clean drinking water, and plagued with ongoing air and water pollution, sickness and a lack of education opportunities.

These are the types of victims of corruption that law enforcement agencies should identify and seek to compensate. There may be an opportunity for the Serious Fraud Office to assist the Congolese victims. The closure and subsequent acquisition of the KMT mine is reportedas being part of the SFOsinvestigationinto Eurasian Natural Resources Corporation (ENRC), one of the SFOs longest-running cases. In January 2020, the first group of 16 Congolese residentsstepped forwardas potential victims in the case.

In overseas cases, compensation orders may present an ethical problem. The prosecuting country can appear to be enriching itself while providing little to those enduring the repercussions of corruption. This issue was debated by world leaders at the International Anti-Corruption Summitof 2016in which the UK pledged not only to expose, pursue and punish those involved in corruption but also to compensate overseas victims of corruption and return stolen assets.

In 2018, the UK adopted the General Principles to compensate overseas victims (including affected States) in bribery, corruption and economic crime cases(theCompensation Principles) in answer to that commitment. The principles are progressive in establishing that UK law enforcement agencies shall identify overseas victims in all relevant cases and consider compensating them by using whatever legal mechanisms are available.

The Compensation Principles are a promising step forward, but they lack a comprehensive definition of overseas victims. To date, affected states are the primary recipients of the minimal funds being returned, as opposed to affected communities or individuals. While in some cases the state might be the appropriate recipient of such funds, in other cases it is not.

For example, where senior members of the government played a direct role in the corruption, not only is there a significant risk that the funds might be re-corrupted, it also sends a message that those responsible can act with impunity. In addition, by not directly compensating individuals or communities harmed by corruption, access to remedy is weakened. It risks creating a two-tier system between overseas victims of corruption and victims of other crimes.

Law enforcement agencies like the SFO should deepen their understanding of the victims of overseas corruption, quantify the harm and loss caused, and find the best legal avenues for compensation. Not doing so will render the Compensation Principles meaningless and the fight against corruption less effective and less fair.

The full RAID report can be viewed here.

View post:

When will prosecutors identify and compensate overseas victims of corruption? - The FCPA Blog

Operation Unhappy Meal: How the FBI trapped the million-dollar McDonalds Monopoly cheats – The Independent

Everyone thought you never had a chance to win the McDonalds Monopoly game, says James Lee Hernandez, but you never really knew why. Hernandez, who, along with Brian Lazarte, wrote and directed HBOs six-part true-crime docuseries McMillions, now knows exactly why.

From 1989 to 2001 in the US, the fast food chains promotional competition, in which customers would collect Monopoly-style pieces which could be exchanged for prizes worth up to $1m, was hijacked by a mysterious crime ring. FBI investigators believe that almost every person who came forward to claim a high-value prize during those years was part of one giant scheme to defraud the game.

McMillions airs in the UK on Wednesday on Sky Documentaries, and tells the story of the Monopoly scam through extensive interviews with the perpetrators and investigators. It harkens back to growing up during the time of this thing, the heyday of this game, through the Nineties, says Hernandez. Brian and I both grew up during this time. My first job when I was 16 years old was at McDonalds.

Sharing the full story, not just the headlines

The story begins midway through, in an FBI field office in 2001, as rookie investigator Doug Mathews settles into the bureaus branch in Jacksonville, Florida. It was an office with a reputation as a sleepy hollow, where big, headline-grabbing cases seldom reared their heads.

At the time, the Jacksonville office was primarily focused on investigating healthcare fraud. On a whim, Mathews, who claimed he was bored to death with this healthcare garbage, chased up a lead scrawled on a Post-It Note: a tip-off claiming that the lucrative McDonalds Monopoly game was rigged.

FBI agent Doug Mathews was at the heart of the investigation into the fraud (HBO/Sky UK)

Digging into the claim, the FBI worked out that three of the games winners, who claimed to have chanced upon the winning Monopoly pieces, were related. After determining that McDonalds werent just rigging the game themselves, the bureau began an elaborate investigation that involved wiretaps, informants and even an undercover sting operation, which is thrillingly recreated in what is perhaps the series best sequence.

We had really never seen anybody show the FBI in a light that really, truly represents them, Lazarte says. Its always the FBI finds one clue, they make one phone call, and they know everything. No! Its a series of people working together to make this case happen.

Through their wiretap, the Jacksonville FBI recorded conversations between the competition winners and mutual third parties, known as recruiters. Patterns emerged. Several of the suspects made reference to a figure known only as Uncle Jerry, whom the Feds soon identified as the schemes ringleader.

As McMillions painstakingly details the FBIs search for Uncle Jerry, we are afforded an intimate look at the human side of the bureau, the conflicting personalities that were thrown into the mix. Everyone has seen movies about federal officers, FBI agents, federal prosecutors, said Hernandez. Usually theyre just robots with suit jackets.

Meeting people, and meeting Mathews, and seeing what goes into an actual FBI investigation taking this really small kernel of information and exploding it into a huge case was fascinating to us.

Mathews, in particular, is a jovial personality with a childlike grin; the antithesis of what FBI agents are supposed to be. Early in McMillions, he describes his partner and superior, Rick Dent, as having about as much personality as this piece of wood right here, tapping on his desk. The series creators say that the humour was in-built; the story couldnt have been told any other way.

We always liked the idea of letting funny characters be funny. Were not making fun of them; were just letting them be who they are, Lazarte says, adding that they chose to lean into the levity in every instance we could.

Eventually, the FBI succeeded in tracking down Uncle Jerry, and obtained enough evidence through the wiretaps to press charges. Warrants were handed down, criminal proceedings were initiated. The trial began in a flurry of press attention, on 10 September 2001. By the next day, the Twin Towers had fallen, McDonalds had vanished from the headlines entirely, and the FBI was a completely different place.

Before 9/11, says Lazarte, these are white collar crime agents. Theyre busting insurance fraud, theyre busting wire fraud and bank fraud. These are the crimes that are important: making sure that people arent getting defrauded. The McDonalds Monopoly case comes in, and it seems important because its a large fraud thats nationwide. But immediately, when 9/11 happened, the lens completely changes. All of a sudden, FBI agents are full force becoming anti-terrorism agents.

They rightfully just shifted gears and something like the McDonalds Monopoly game doesnt seem so bad any more. Thats a big reason why people dont even know about it, because the news completely focuses for the next year or more on the fallout of 9/11.

The investigation which FBI agents had jokingly called Operation Fallen Arches and Operation Unhappy Meal before settling on Operation Final Answer no longer seemed like a career-defining case, even though, by this point, investigators had exposed ties to the Italian mafia, and had indicted more than 50 people. The 9/11 terrorist attacks seem to reinforce the idea that defrauding Ronald McDonald was, ultimately, pretty low-stakes stuff.

One of the coveted winning Monopoly game pieces (HBO/Sky UK)

But, insists Lazarte, the severity of the crime shouldnt be undersold. People assume that this was a victimless crime, he says. Stealing from a major billion-dollar corporation, you wont hurt anybody youre just cheating at the game. But the actions that all these people participated in had a dramatic effect: on their own lives, on the relationships of those people, on their job opportunities. Theyre forever painted as federal criminals as a result of this greed.

Despite McMillions extensive interview footage the six-episode structure allows ample time to conduct a deep dive into the investigations more charismatic personnel there are some voices missing from the finished product. For some, this is because they are no longer alive; others simply refused to participate, such as the taciturn, very gracious, very private FBI agent Rick Dent.

McMillions untangles its mystery slowly, leaving you guessing until the very end. How did the winning pieces make their way into the hands of the mafia? Who tipped off the FBI in the first place? Where did all the money go? Who was Uncle Jerry? Hernandez and Lazarte comprehensively, and patiently, answer most of the questions, leaving just enough room for a bit of speculation. As Hernandez points out: Sometimes, the legend is better than the real thing.

The story of the Monopoly scam is a tale of human fallibility, of weakness and manipulation, but the McMillions directors retain some sympathy for its perpetrators. You could easily villainise them, but then you realise they were just opportunists, says Hernandez.

McMillions is airing on Sky Documentaries and NOW TV on Wednesday 27 May at 9pm

Follow this link:

Operation Unhappy Meal: How the FBI trapped the million-dollar McDonalds Monopoly cheats - The Independent

McMillions takes us into the heart of the McDonald’s Monopoly scandal – but whose side are we on? – inews

CultureThis is surely almost a victimless tale - a bit of harmless fraud which mainly impacted McDonald's executives

Thursday, 21st May 2020, 4:43 pm

Can a story ever be too good for documentary? The McDonalds McMillions case is one of the great modern frauds, an almost-victimless tale to warm the heart of everyone who hears it except perhaps McDonalds executives and a few innocents who were unwittingly caught up in a federal crime.

Over an astonishingly long period, between 1989 and 2001, a disgruntled ex-cop called Jerome Jacobson defrauded Ronald & Chums of many millions of dollars through the chains popular Monopoly promotion, in which diners would collect prize tokens attached to McDonalds packaging.

The scheme was ingenious. As the head of security for Simon Marketing, the company that ran the Monopoly game, Jacobson was charged with transporting the winning tokens. They were kept in a secure briefcase, and in theory Jacobson was accompanied at all times by a McDonalds accountant.

i's TV newsletter: what you should watch next

i's TV newsletter: what you should watch next

But their work involved lots of flights within the US. While they waited for their flights to be called, Jacobson would excuse himself to use the bathroom and take the briefcase with him. In the cubicle, he would swap the winning tokens for non-winning ones. Then he would sell on the tokens for a percentage of the winnings, at first to family and friends, then later to an expanding ring of criminals.

Between 1995 and 2000, he and his accomplices won almost every top prize in north America, including cash and sports cars, to a value of $24m. More than 50 people were convicted. Youd need a heart of stone not to laugh, and I write as someone who played McDonalds Monopoly a lot between 1995 and 2000.

The story begs for the screen treatment. Jacobson was convicted on 10 September 2001, so the news was buried by other events. It only came to wider attention after a Daily Beast article in 2018. Ben Affleck and Matt Damon are said to be working on a film.

In the meantime, we have McMillions, a six-part HBO documentary that retells the story through interviews with some of the people involved and anonymous reconstructions. Its well made, but it suffers from its angle of approach.

Our eyes and ears are the FBI agents and McDonalds employees who set about uncovering the scam.

Except for the most egregious crimes, it always feels a bit iffy to find ourselves on the cops team. When the victim is a multibillion-dollar hamburger corporation, it rankles. Theres a reason Oceans 11 takes the side of the robbers, and one rarely sees Robin Hood told from the Sheriffs point of view.

We long to know what makes the fradster tick

Documentaries with difficult or ambiguous subjects work best when we see both sides. The most gripping moments in Ken Burns epic documentary about the Vietnam War were the interviews with the Viet Cong soldiers. Burns criticised The Last Dance, ESPNs recent documentary about the Chicago Bulls, for complicity with its main subject, Michael Jordan.

The hole at the heart of McMillions is Jacobson himself. We long to know what made him tick.

As with the Who Wants to Be a Millionaire? scam, there were questions about whether a crime was being committed, especially by the people who bought the winning tickets. Is it a federal fraud, or just canny players discovering a few tricks against McDonalds? The brilliance of James Grahams Quiz was to present the Ingrams, Chris Tarrant and the ITV executives as rounded human beings without passing judgement.

A documentary without the Ingrams wouldnt have been half as interesting. When it comes to recounting real-life events, sometimes only drama will do.

See original here:

McMillions takes us into the heart of the McDonald's Monopoly scandal - but whose side are we on? - inews

Generation Bio tees up $125M IPO to push next-gen gene therapies – FierceBiotech

Another preclinical-stage biotech is taking to the public marketsGeneration Bio filed for a $125 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The deal comes on the heels of a $110 million venture round tagged to bankroll its lead programs: liver-targeted therapies for hemophilia A and phenylketonuria (PKU). Together, the funds will allow Generation Bio to finish IND-enabling studies for both programs as well as kick off a clinical trial for one, according to a securities filing.

That phase 1 study is still a ways away, though: [All] of our programs are currently in the early stage of development, including our programs in PKU and hemophilia A, and we have not yet identified a product candidate for any of our programs, the company said in the filing.

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, well do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: Generation Bio grabs a $110M round to ramp up work on next-gen gene therapies

Generation Bio plans to gather enough data to pick its candidates over the course of this year, with IND-enabling studies slated for 2021 and IND applications for 2022.

We anticipated submitting IND applications for additional programs in 2023 and beyond, the company said in the filing.

The companys pipeline includes treatments for diseases of the eye as well as three other liver disease programs, including treatments for Wilson disease and Gaucher disease. Its most advanced retina disease program targets Leber congenital amaurosis 10, or LCA10, a rare type of blindness caused by mutations in the CEP290 gene. Thats the same form of LCA that Editas Medicines and Allergan are aiming at with a CRISPR-based gene editing treatment.

RELATED: Editas, Allergan kick off long-awaited in vivo CRISPR trial

Generation Bios programs are based on its non-viral gene therapy platform that uses lipid nanoparticles to deliver closed-ended DNA (ceDNA) to diseased tissue.

Our vision is to develop re-dosable, long-lasting gene therapies manufactured at a scale that leaves no patient or family behind, said Geoff McDonough, M.D., president and CEO of Generation Bio, earlier this year.

See the article here:

Generation Bio tees up $125M IPO to push next-gen gene therapies - FierceBiotech

Expression Therapeutics Announces IND Approval by the FDA for Hemophilia A Gene Therapy – PRNewswire

ATLANTA, May 26, 2020 /PRNewswire/ -- Expression Therapeutics has announced that it has received clearance by the United States Food and Drug Administration (FDA) to proceed following review of its Investigational New Drug Application (IND) for clinical testing of its novel lentiviral vector-based gene therapy ET3 for hemophilia A. Hemophilia A is the most common severe congenital bleeding disorder and afflicts approximately 1 in 8,000 people. Without treatment, severe hemophilia is crippling and fatal by late adolescence to early adulthood.

The ET3 gene therapy developed by Expression Therapeutics combines innovative platform technologies in protein bioengineering and tissue-directed expression. ET3 consists of autologous mobilized peripheral blood stem and progenitor cells transduced with a recombinant lentiviral vector, encoding a bioengineered coagulation factor VIII transgene designed for highlevel expression at low vector copy number. In the ET3 trial, subjects will be preconditioned with low-dose stem and immune cell suppressing agents prior to receiving a single infusion of ET3. The high-expression factor VIII can correct the bleeding tendency in hemophilia A. The duration of ET3 activity is expected to be the normal lifetime of the patient. Expression Therapeutics expects to initiate a Phase 1 clinical trial titled ET3-201 at Emory University and enroll patients shortly.

"We are extremely pleased that the FDA has granted permission to proceed with this clinical study," said Trent Spencer, Ph.D., President of Expression Therapeutics and Director of the Cell and Gene Therapy Program in the Aflac Cancer and Blood Disorders Center at Emory University.

Hematopoietic stem and progenitor cell lentiviral gene therapy is currently the only approach that offers the possibility of permanent cure of hemophilia A and provides an opportunity to reach both pediatric and adult populations.

"We are very excited to get the hemophilia A clinical trial underway, the first of six gene therapy products currently under development at Expression Therapeutics," said Mohan Rao, Ph.D., CEO of Expression Therapeutics.

Expression Therapeutics is a biotechnology company based in Atlanta. The current therapeutic pipeline includes advanced gene therapies for hemophilia A and B; neuroblastoma, T-cell leukemia/lymphoma, and acute myeloid leukemia (AML); and primary immunodeficiencies such as hemophagocytic lymphohistiocytosis (HLH).

For inquiries, please contact:

Ashley WalshDirector of Corporate DevelopmentExpression Therapeutics 1860 Montreal RoadTucker, Georgia 30084[emailprotected]+1 312.637.2975

SOURCE Expression Therapeutics

http://www.expressiontherapeutics.com

Excerpt from:

Expression Therapeutics Announces IND Approval by the FDA for Hemophilia A Gene Therapy - PRNewswire

Novartis’ gene therapy approved in Europe, talks ongoing on price – BioPharma-Reporter.com

In March, Novartis was able to announce that Zolegensma (onasemnogene abeparvovec) that it had received a positive opinion on its application for marketing approval by the European Medicines Agency.

Yesterday this was followed up by the announcement that the European Commission (EC) had provided the gene therapy conditional approval for the treatment of patients with spinal muscular atrophy. The treatment will be available for those with a bi-allelic mutation in the SMN1 gene and a diagnosis of SMA type 1; or for patients with SMA with the mutation and up to three copies of the SMN2 gene.

The company added that the approval also covers babies and young children with SMA, up to a body weight of 21kg (46 pounds).

Novartis stated that the treatment will be made available immediately in France and that Germany would gain access shortly.

In terms of pricing, the company noted that it was working with stakeholder organizations across Europe, so that pricing would "work within existing, local pricing and reimbursement frameworks."

The pricing has proved a controversial aspect of the one-time gene therapy, which entered the US market at a cost of $2.1m (1.9m) per patient.

In its announcement, the company countered that the cost of caring for a child with SMA to the healthcare system is approximately 2.5m to 4m for 10 years of care.

In fourth quarter results, the treatment saw sales of $170m in the US.

Link:

Novartis' gene therapy approved in Europe, talks ongoing on price - BioPharma-Reporter.com

NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product – Business Wire

LYON, France & PARIS--(BUSINESS WIRE)--Regulatory News:

Novasep, a leading supplier of services and technologies for the life sciences industry, and Lysogene (Paris:LYS)(FR0013233475 LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the signature of an agreement for the development and manufacturing of LYS-GM101, an AAVrh10-based gene therapy drug candidate for the treatment of GM1 Gangliosidosis, a rare neuronopathic lysosomal storage disorder.

With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogenes lead gene therapy product, LYS-SAF302, currently in clinical phase 2/3.

Mark Plavsic, Lysogenes Chief Technical Officer said: Following the successful relationship developed during the past 4 years, I am very pleased to continue working with Novasep, which is emerging as a true leader in gene therapy development and manufacturing. By extending our collaboration, we secure the clinical production of our experimental treatment for GM1 gangliosidosis and take an option for a smooth and effective technical transfer to a future commercial process.

Cedric Volanti, Novaseps President of Biopharma Solutions said: "We, at Novasep, are delighted to pursue and extend our partnership with Lysogene. Novasep will bring its expertise and mobilize its production capacities to first help Lysogene in the clinical development of its innovative gene therapy treatment for GM1 gangliosidosis; and secondly, to shorten the transition to a commercial product manufacturing by ensuring a smooth process transfer to our commercial manufacturing facility."

About Lysogene

Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1/3 clinical trial in GM1 gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. http://www.lysogene.com.

About Novasep

Novasep provides cost-effective and sustainable manufacturing solutions for the life sciences industries.

With 20 years experience in the development and manufacturing of biomolecules, Novasep offers a full range of CDMO services for:

- Viral vectors (AAV, Adenovirus, Lentivirus, HSV, VSV, VEEV) for cell and gene therapy, immunotherapy and vaccination, from process development to cGMP production

- Fill & Finish services for viral vectors, attenuated and live viruses, mAbs, plasmids and other biologics, from formulation to packaging

As part of its growth strategy Rise-2, Novasep recently unveiled a new facility, Senrise-IV, dedicated to the commercial production of viral vectors which has been completed last year by Senefill, a new Fill & Finish commercial facility for aseptic operations. Both facilities located in Seneffe, Belgium, will contribute to the success of biopharmaceuticals projects.

Read the rest here:

NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product - Business Wire

Evox Therapeutics Appoints Martin Andrews as Non-Executive Director – BioSpace

Senior industry executive with specialist expertise in rare diseases

OXFORD, England, May 27, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Martin Andrews as a Non-Executive Director. Martin is a highly experienced senior pharmaceutical executive with broad R&D, commercial and operational experience, and has deep specialist expertise in rare diseases, gene therapy and vaccines.

Martin is an experienced Non-Executive Director and commercial leader, with a strong track record of strategy development and operational delivery. He has had a long and successful career at GlaxoSmithKline, where he has held many senior positions. Most recently, Martin was Senior Vice President, Rare Diseases. Here, he led the global rare disease business and oversaw the development of a portfolio of ex vivo gene therapies, and the launch of Strimvelis, the world's first life-saving gene therapy for children. Furthermore, under his leadership, GlaxoSmithKline transferred its gene therapy portfolio to Orchard Therapeutics. Prior to that, Martin was Senior Vice President, Global Vaccines Commercial, where he led the development of the growth strategy and transformation of the commercial capability in GlaxoSmithKline's Vaccines division.

Martin has previously held Board positions at Orchard Therapeutics and the Alliance for Regenerative Medicine. He is currently a Non-Executive Director of Freeline Therapeutics, where he brings his commercial expertise to their gene therapy portfolio of drugs.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented:

"We're very pleased to welcome Martin as a Non-Executive Director. With his rare disease drug development experience and strong track-record of commercial success, Martin will be a great asset to the company. His expertise will play an important role in helping guide our business growth."

Commenting on his appointment, Martin Andrews said:

"I'm delighted to be joining the Board of Evox. This is an exciting period for the Company and I believe its technology has the potential to transform how medicines are developed and delivered for patients with conditions that are not possible to treat adequately today, especially those with rare diseases. I am thrilled to be part of the team and look forward to contributing."

About Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox's mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.

For further information visit: http://www.evoxtherapeutics.com

View original content:http://www.prnewswire.com/news-releases/evox-therapeutics-appoints-martin-andrews-as-non-executive-director-301065071.html

SOURCE Evox Therapeutics

Originally posted here:

Evox Therapeutics Appoints Martin Andrews as Non-Executive Director - BioSpace

New Zolgensma ‘inflection point’ is here as Novartis snags EU nod for SMA gene therapy – FiercePharma

As the number of U.S. spinal muscular atrophy (SMA) patients Zolgensma treats each quarter stabilizes, Novartis is counting on a set of inflection points for future growth. Now, it has one.

After a manufacturing-related delay, Novartis has won conditional approval in the EU for the one-time gene therapy to treat patients with a clinical diagnosis of SMA type 1 and others with up to three copies of the SMN2 backup gene, the company said Monday.

Zolgensmas EU label is different from the U.S. version. While its approved by the FDA to treat children less than 2 years of age, the EMA allows it in babies and young children who weigh up to 21 kilograms. According to a Pediatric Neuromuscular Clinical Research natural history study of SMA, almost all patients under the age of 5 will be under 21 kg.

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

The number of SMN2 genes determines the severity of the disease, with SMA type 1 the most severe form. The U.S. approval is for all SMA types, but the EU nod leaves out a small proportion of patients who could develop mild, late-onset type 3 or type 4 SMA. Patients with type 3 SMA, sometimes called Kugelberg-Welander disease, may have up to four copies of SMN2.

The difference could havemixed effectson Zolgensmas opportunity in the two territories. For existing patients already on Biogens Spinraza, Zolgensma could steal share from older patients in the EU. But for new patients, the FDA label enables the Novartis drug to reach more patients if diagnosis through newborn screening is widely adopted and patients are treated early.

Zolgensma has reached a steady state where it treats about 100 patients per quarter in the U.S., Novartis CEO Vas Narasimhan recently told investors. That translated into $170 million sales in the first quarter, a slight quarter-over-quarterdecline due to COVID-19. The companys expecting approvals in new countriesand new indications to be inflection points that will eventually propel the drug to blockbuster sales.

RELATED:The top 10 drug launches since 2017 | 7. Zolgensma

It had the first point in March with a Japanese nod, also for patients under 2 years old. Last week, the Japanese government approved Zolgensmas price at 167 million yen ($1.55 million), lower than its U.S. list price of $2.12 million.

In Europe, final pricing and reimbursement decisions will be determined at the local level, a spokesperson at Novartis AveXis gene therapy unit told FiercePharma. Cumulative healthcare costs per SMA patient are estimated at between 2.5 million to 4 million over the first 10 years, the company said.

Novartis said its working with European countries local regulators on an access program called Day One. Its designed to provide fast access to Zolgensma even before national pricing and reimbursement agreements are in place, a process that sometimes takes years. The program offers several options such as deferred payments and installment over years as well as outcomes-based rebates. The drug has been made available in France under the countrys Temporary Authorization for Use pathway, and access is expected shortly in Germany, the Swiss drugmaker said.

Beyond the already-approved intravenous version, Novartis is developing a formulation that delivers Zolgensma through an injection into the spinal canal so that it can reach older patients up to 5 years of age in the U.S. Its working with the FDA to resolve a partial clinical hold slapped on the high dose of the intrathecal formulation before it can file for an approval.

Currently, AveXis makes Zolgensma at its site in Libertyville, Illinois. It also has plants in Durham, North Carolina, and Longmont, Colorado. The latter two are expected to be licensed in 2021, the company spokesperson said, adding that it has no plans for a manufacturing facility in the EU at this point.

Continue reading here:

New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy - FiercePharma